Latest Breaking News On - Exclusive license - Page 9 : comparemela.com

VerImmune and Fosun Pharma enter into an Exclusive License and Option Agreement for VerImmune s Virus-inspired Particle (ViP) platform as Novel Immunotherapies in China

Washington DC (PRWEB) May 20, 2022 VerImmune Inc. (“VerImmune”), a privately-held biotechnology company developing a novel therapeutic virus-inspired

Hong kongJoshua wangWu yifangFosun pharmaMacau special administration regionsSinopharm co ltdShanghai fosun pharmaceutical group co ltdVerimmune incFosun pharma united statesShanghai fosun pharmaceuticalExclusive licenseChinese mainlandVerimmune founderVirus inspired particleAnti tumor immune redirectionPress release

Cocrystal Pharma, Inc (COCP) Reports Q1, Provides Updates on its Antiviral Development Programs and Milestones

Cocrystal Pharma, Inc (COCP) Reports Q1, Provides Updates on its Antiviral Development Programs and Milestones
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

South africaUnited kingdomJody cainSam leeJames martinJules abrahamResearch collaboration agreementKansas state university research foundationWorld health organization global hepatitisFederal reserveMerck sharp dohme corpCocrystal pharma incNorovirus programClinical research organizationHepatitisc programSevere acute respiratory syndrome

Junshi Biosciences Announces Full Year 2021 Financial Results and Provides Corporate Updates | Comunicados | Edición USA

Junshi Biosciences Announces Full Year 2021 Financial Results and Provides Corporate Updates | Comunicados | Edición USA
efe.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from efe.com Daily Mail and Mail on Sunday newspapers.

United statesHong kongHong kong special administrative regionHong kong generalSan franciscoMacau generalJuntop biosciencesJunshi bioscienceCong liJunshi biosciencesJunshi bioscienceszhiShanghai junshi biotechnology co ltdCompany the shareholdersLingang productionInstitute of microbiologyCoherus biosciences inc

Junshi Biosciences Announces Full Year 2021 Financial Results and Provides Corporate Updates

-Tackling the COVID-19 pandemic challenge with multi-pronged strategies - Pipeline progressed and expanded substantially SHANGHAI, China, March 31, 2022 (GLOBE NEWSWIRE) Shanghai Junshi

United statesHong kongHong kong special administrative regionHong kong generalMacau generalJuntop biosciencesJunshi bioscienceCong liJunshi biosciencesZhi liShanghai junshi biotechnology co ltdCompany the shareholdersLingang productionInstitute of microbiologyCoherus biosciences incWigen biomedicine technology shanghai co ltd

VectivBio Announces Japan License Deal and Loan Facility Agreement, Providing up to $117 Million to Fuel the Company Through Key Catalysts

Exclusive License with Asahi Kasei Pharma to develop and commercialize Apraglutide in Japan includes $30 million upfront cash payment, eligibility for up to $170 million in development and commercial. | March 30, 2022

Yoshikazu aokiClaudia daugustaLuca santarelliAsahi kasei pharmaMaurizio petitbonExchange commissionExchange commission onAsahi kasei pharma corporationAsahi kasei pharma missionVectivbio holding ag nasdaqExclusive licenseKreos capitalBusiness updateChief executive officerAsahi kaseiGeneral partner